# US 2003/0077576 A1 · Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077576 A1
- Document ID: US20030077576A1
- Status: Published application
- Kind: A1
- Application number: 10/102,062
- Filed: 2002-03-20
- Published: 2003-04-24
- Earliest claimed: 2001-03-20
- Inventors: Joann Trial; Roger Rossen; Holly Birdsall
- Web page: https://patentgrep.com/patent/US20030077576A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/56988: {HIV or HTLV}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention is drawn to methods of detecting and monitoring a subject at risk for opportunistic infection. More particularly, the methods comprise monitoring key monocyte functions and surrogate cell surface markers on monocytes to predict subjects at risk for opportunistic infection. Specific monocyte key functions comprise measurements of phagocytic activity and transendothelial migration. Another aspect of the present invention is a kit comprising the compositions of the present invention used to detect or monitor a subject at risk for opportunistic infection.

## Claims

### Claim 1

A method of detecting a subject at risk for opportunistic infection comprising the steps of:
obtaining a sample from said subject;
incubating said sample with at least one antibody specific to cell surface markers;
determining the amount of cell surface markers bound to antibodies by immunological detection; and
comparing the amount of cell surface markers bound to antibodies in said sample to an amount of cell surface markers bound to antibodies in a control sample, wherein a difference in the amount of said sample compared to said control sample detects a subject at risk for opportunistic infection.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample is whole blood, peripheral blood mononuclear cells or bone marrow.

### Claim 3 (depends on 1)

The method of claim 1, wherein said immunological detection is selected from the group consisting of radioimmunoassay, enzyme-linked immunosorbent assay, immunoblotting and immunofluorescence.

### Claim 4 (depends on 3)

The method of claim 3, wherein said immunodetection is by immunofluorescence using flow cytometry.

### Claim 5 (depends on 1)

The method of claim 1, wherein said subject is immunosuppressed.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject suffers from a condition selected from the group consisting of trauma, chronic disease, chronic infection, acute infection, major surgery, immunosuppressive therapy, inherited immunodeficiency disease and cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein said subject is HIV-infected.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cell surface marker is selected from the group of antigens consisting of CD 14, CD11a, CD11b, CD16, CD49e, CD62L, CD64, CD32, CD40, CD86, proteinase 3, and ANCA.

### Claim 9 (depends on 8)

The method of claim 8, wherein said cell surface marker is CD40 or CD86.

### Claim 10 (depends on 8)

The method of claim 8, wherein said cell surface marker is CD49e or CD32.

### Claim 11 (depends on 1)

The method of claim 1, wherein said cell surface marker is a monocyte surface marker.

### Claim 12 (depends on 1)

The method of claim 1, wherein said antibody is selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD 14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, anti-proteinase-3, NKI-L16, 41H16, anti-CD32, anti-CD40, anti-CD86 and anti-ANCA.

### Claim 13 (depends on 12)

The method of claim 12, wherein said antibody is anti-CD40 or anti-CD86.

### Claim 14 (depends on 12)

The method of claim 12, wherein said antibody is anti-CD49e or anti-CD32.

### Claim 15 (depends on 1)

The method of claim 1, wherein said antibodies are monoclonal.

### Claim 16 (depends on 1)

The method of claim 1 further comprising incubating said sample with more than one antibody specific to cell surface markers.

### Claim 17 (depends on 1)

The method of claim 1 further comprising measuring fibronectin fragments.

### Claim 18 (depends on 17)

The method of claim 17, wherein said fibronectin fragments are 110 kD or 120 kD.

### Claim 19

A method of detecting a subject at risk for opportunistic infection comprising the steps of:
obtaining a blood sample from said subject;
performing a functional assay;
determining the amount of functional activity in said sample, by immunological detection; and
comparing the amount of functional activity in said sample to an amount of functional activity in a control sample, wherein a difference in the amount of said sample compared to said control sample detects a subject at risk for opportunistic infection.

### Claim 20 (depends on 19)

The method of claim 19, wherein said sample is whole blood, peripheral blood mononuclear cells or bone marrow.

### Claim 21 (depends on 19)

The method of claim 19, wherein said functional assay is a measure of phagocytosis.

### Claim 22 (depends on 21)

The method of claim 21, wherein unstimulated and stimulated phagocytosis is measured by measuring the levels of fluorochrome labeled particles.

### Claim 23 (depends on 22)

The method of claim 22, wherein phagocytosis is stimulated by IL-15.

### Claim 24 (depends on 19)

The method of claim 19, wherein said functional assay is a measure of transendothelial migration.

### Claim 25 (depends on 19)

The method of claim 19, wherein said functional assay is a measure of spontaneous oxidative burst.

### Claim 26 (depends on 25)

The method of claim 25, wherein said spontaneous oxidative burst is a measure of the level of reactive oxygen intermediates.

### Claim 27 (depends on 19)

The method of claim 19, wherein said immunological detection is by immunofluorescence using flow cytometry.

### Claim 28 (depends on 19)

The method of claim 19 further comprising measuring a monocyte identification cell surface marker as an identifier.

### Claim 29 (depends on 28)

The method of claim 28, wherein said monocyte marker is CD14.

### Claim 30 (depends on 19)

The method of claim 19 further comprising measuring a neutrophil identification cell surface marker as an identifier.

### Claim 31 (depends on 30)

The method of claim 30, wherein said neutrophil marker is CD16.

### Claim 32

A method of detecting a subject at risk for opportunistic infection comprising the steps of:
obtaining a sample from said subject, wherein said sample is whole blood, peripheral blood mononuclear cells or bone marrow;
incubating said sample with at least one antibody specific to cell surface markers, wherein said antibodies are selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, anti-proteinase-3, NKI-L16, 41H16, anti-CD32, anti-CD40, anti-CD86 and anti-ANCA;
determining the amount of antibodies bound to cell surface markers by immunological detection; and
comparing the amount of antibodies bound to cell surface markers in said sample to an amount of cell surface markers bound to antibodies in a control sample, wherein said control sample is obtained from a normal individual and a difference detects a subject at risk for opportunistic infection.

### Claim 33

A method for predicting an HIV subject at risk for opportunistic infection comprising the steps of:
obtaining a sample from said subject;
incubating said sample with at least one antibody specific to monocyte cell surface markers;
determining the amount of monocyte cell surface markers bound to antibodies in said sample by immunological detection; and
comparing the amount of monocyte cell surface markers bound to antibodies in said sample to an amount of monocyte cell surface markers bound to antibodies in a control sample, wherein a difference in the amount of said sample compared to said control sample detects an HIV subject at risk for opportunistic infection.

### Claim 34 (depends on 33)

The method of claim 33, wherein said monocyte cell surface markers are selected from the group of antigens consisting of CD11a, CD11b, CD 14, CD16, CD49e, CD62L, CD64, NKI-L16, CD32, CD40, CD86, 41H16, ANCA, and proteinase-3.

### Claim 35 (depends on 33)

The method of claim 33 further comprising determining phagocytic activity in said sample.

### Claim 36 (depends on 33)

The method of claim 33 further comprising determining the production of reactive oxygen intermediates.

### Claim 37 (depends on 33)

The method of claim 33 further comprising determining transendothelial migration.

### Claim 38

A method for monitoring an HIV subject at risk for opportunistic infection comprising the steps of:
obtaining a sample from said subject;
incubating said sample with at least one antibody specific to monocyte cell surface markers;
determining the amount of monocyte cell surface markers bound to antibodies in said sample by immunological detection; and
comparing the amount of monocyte cell surface markers bound to antibodies in said sample to an amount of monocyte cell surface markers bound to antibodies in a control sample.

### Claim 39 (depends on 38)

The method of claim 38, wherein comparing comprises obtaining additional samples from said subject and comparing to control.

### Claim 40 (depends on 38)

The method of claim 38, wherein comparing comprises obtaining additional samples from said HIV subject and comparing the samples from said HIV subject.

### Claim 41 (depends on 38)

The method of claim 38, wherein the step of obtaining said sample is repeated for multiple days.

### Claim 42 (depends on 38)

The method of claim 38, wherein said monocyte cell surface markers are selected from the group of antigens consisting of CD11a, CD11b, CD14, CD16, CD49e, CD62L, CD64, NKI-L16, CD32, CD40, CD86, 41H16, ANCA, and proteinase-3.

### Claim 43 (depends on 38)

The method of claim 38 further comprising determining phagocytic activity in said sample.

### Claim 44 (depends on 38)

The method of claim 38 further comprising determining the production of reactive oxygen intermediates.

### Claim 45 (depends on 38)

The method of claim 38 further comprising determining transendothelial migration.

### Claim 46

A method of monitoring a subject at risk for opportunistic infection comprising:
obtaining a sample from said subject, wherein said sample is whole blood, peripheral blood mononuclear cells or bone marrow;
incubating said sample with at least one antibody specific to cell surface markers, wherein said antibodies are selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, anti-proteinase-3, NKI-L16, 41H16, anti-CD32, anti-CD40, anti-CD86 and anti-ANCA;
determining the amount of antibodies bound to cell surface markers by immunological detection; and
comparing the amount of antibodies bound to cell surface markers in said sample to an amount of cell surface markers bound to antibodies in a control sample, wherein said control sample is obtained from a normal.

### Claim 47 (depends on 46)

The method of claim 46, wherein comparing comprises obtaining additional samples from said subject and comparing to control.

### Claim 48 (depends on 46)

The method of claim 46, wherein comparing comprises obtaining additional samples from said subject and comparing the samples from said subject.

### Claim 49 (depends on 46)

The method of claim 46, wherein the step of obtaining said sample is repeated for multiple days.

### Claim 50

A method for monitoring a subject at risk for opportunistic infection comprising the steps of:
obtaining a sample from said subject;
incubating said sample with at least one antibody specific to monocyte cell surface markers;
determining the amount of monocyte cell surface markers bound to antibodies in said sample by immunological detection; and
comparing the amount of monocyte cell surface markers bound to antibodies in said sample to an amount of monocyte cell surface markers bound to antibodies in a control sample.

### Claim 51 (depends on 50)

The method of claim 50, wherein comparing comprises obtaining another sample from said subject and comparing to control.

### Claim 52 (depends on 50)

The method of claim 50, wherein comparing comprises obtaining another sample from said subject and comparing the samples from said subject.

### Claim 53 (depends on 50)

The method of claim 50, wherein obtaining said sample is repeated for multiple days.

### Claim 54 (depends on 50)

The method of claim 50, wherein said monocyte cell surface markers are selected from the group of antigens consisting of CD11a, CD11b, CD16, CD14, CD49e, CD62L, CD64, NKI-L16, CD32, CD40, CD86, 41H16, ANCA and proteinase-3.

### Claim 55 (depends on 50)

The method of claim 50 further comprising determining phagocytic activity in said sample.

### Claim 56 (depends on 50)

The method of claim 50 further comprising determining the production of reactive oxygen intermediates.

### Claim 57 (depends on 50)

The method of claim 50 further comprising determining transendothelial migration.

### Claim 58

A method of monitoring a subject at risk for opportunistic infection over a period of time comprising the steps of:
obtaining a sample from said subject, wherein said sample is whole blood, peripheral blood mononuclear cells or bone marrow;
incubating said sample with at least one antibody specific to cell surface markers, wherein said antibodies are selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16 anti-CD49e, anti-CD62L, anti-CD64, IgG, anti-proteinase-3, NKI-L16, 41H16, anti-CD32, anti-CD40, anti-CD86 and anti-ANCA;
determining the amount of antibodies bound to cell surface markers by immunological detection; and
comparing the amount of antibodies bound to cell surface markers in said sample to an amount of cell surface markers bound to antibodies in a control sample, wherein said control sample is obtained from a normal.

### Claim 59 (depends on 58)

The method of claim 58, wherein the steps of obtaining, incubating, determining and comparing are repeated.

### Claim 60 (depends on 58)

The method of claim 58, wherein monitoring comprises obtaining additional samples from said subject during the course of treatment.

### Claim 61 (depends on 60)

The method of claim 60, wherein said treatment is prophylactic or therapeutic treatment.

### Claim 62 (depends on 59)

The method of claim 59 further comprising determining phagocytic activity in said sample.

### Claim 63 (depends on 59)

The method of claim 59 further comprising determining the production of reactive oxygen intermediates.

### Claim 64 (depends on 59)

The method of claim 59 further comprising determining transendothelial migration.

### Claim 65

A kit for detecting risk of opportunistic infection comprising a container having a panel of antibodies, wherein said antibodies interact with cell surface markers.

### Claim 66 (depends on 65)

The kit of claim 65, wherein said panel of antibodies are selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, NKI-L16, anti-CD32, anti-CD40, anti-CD86, 41H16, anti-ANCA and anti-proteinase-3.

### Claim 67 (depends on 65)

The kit of claim 65, wherein said panel of antibodies are anti-CD40 and anti-CD86.

### Claim 68 (depends on 65)

The kit of claim 65, wherein said panel of antibodies are anti-CD49e and anti-CD32.

### Claim 69 (depends on 65)

The kit of claim 65 further comprising reagents to detect fibronectin fragments.

### Claim 70 (depends on 69)

The kit of claim 69, wherein said fibronectin fragments are 110 kD or 120 kD.

### Claim 71 (depends on 65)

The kit of claim 65, wherein said panel of antibodies are fluorescently labeled and detected using a flow cytometer.

### Claim 72

A kit for detecting risk of opportunistic infection comprising:
a marker that specifically detects ingestion of microorganisms or other particulates as a measure of phagocytic activity; and a monocyte identification marker.

### Claim 73 (depends on 72)

The kit of claim 72 further comprising a neutrophil identification marker.

### Claim 74 (depends on 72)

The kit of claim 72, wherein the monocyte identification marker is CD14.

### Claim 75 (depends on 72)

The kit of claim 72, wherein the neutrophil identification marker is CD16.

### Claim 76

A kit for detecting risk of opportunistic infection comprising at least two different containers, wherein a first container comprises a panel of antibodies to determine cell surface phenotype and a second container comprises markers to determine phagocytosis.

### Claim 77 (depends on 76)

The kit of claim 76, wherein said first container comprises a panel of antibodies selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, NHK-L16, anti-CD32, anti-CD40, anti-CD86, 41H16, anti-ANCA and anti-proteinase-3.

### Claim 78 (depends on 76)

The kit of claim 76, wherein said first container comprises a panel of antibodies comprising anti-CD40 and anti-CD86.

### Claim 79 (depends on 76)

The kit of claim 76, wherein said first container comprises a panel of antibodies comprising anti-CD49e and anti-CD32.

### Claim 80 (depends on 76)

The kit of claim 76, further comprising reagents to detect fibronectin fragments.

### Claim 81 (depends on 80)

The kit of claim 80, wherein said fibronectin fragments are 110 kD or 120 kD.

### Claim 82 (depends on 76)

The kit of claim 76, wherein phagocytosis is determined by measuring the levels of fluorochrome labeled microorganisms or other particles.

### Claim 83 (depends on 76)

The kit of claim 76, further comprising a fluorochrome to measure reactive oxygen intermediates.

### Claim 84 (depends on 83)

The kit of claim 83, wherein reactive oxygen intermediates are generated spontaneously or induced by the addition of bacteria.

### Claim 85

A kit for analyzing monocyte and neutrophil phenotype in an HIV subject comprising a panel of antibodies, wherein said antibodies interact with cell surface markers.

### Claim 86 (depends on 83)

The kit of claim 83, wherein said panel of antibodies are selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, NKI-L16, anti-CD32, anti-CD40, anti-CD86, 41H16, anti-ANCA and anti-proteinase-3.

### Claim 87 (depends on 83)

The kit of claim 83, wherein said panel of antibodies comprises anti-CD40 and anti-CD86.

### Claim 88 (depends on 83)

The kit of claim 83, wherein said panel of antibodies comprises anti-CD49e and anti-CD32.

### Claim 89 (depends on 83)

The kit of claim 83, further comprising reagents to detect fibronectin fragments.

### Claim 90 (depends on 89)

The kit of claim 89, wherein said fibronectin fragments are 110 kD or 120 kD.

### Claim 91 (depends on 83)

The kit of claim 83 further comprising markers to measure phagocytosis.

### Claim 92 (depends on 91)

The kit of claim 91, wherein phagocytosis is determined by measuring the levels of fluorochrome labeled microorganisms or other particles.

### Claim 93

A kit for monitoring risk of opportunistic infection comprising:
a marker that specifically detects ingestion of microorganisms or other particulates as a measure of phagocytic activity; and a monocyte identification marker.

### Claim 94 (depends on 93)

The kit of claim 93 further comprising a neutrophil identification marker.

### Claim 95 (depends on 93)

The kit of claim 93, wherein the monocyte identification marker is CD14.

### Claim 96 (depends on 93)

The kit of claim 93, wherein the neutrophil identification marker is CD16.

### Claim 97

A kit for monitoring risk of opportunistic infection comprising at least two different containers, wherein a first container comprises a panel of antibodies to determine cell surface phenotype and a second container comprises markers to determine phagocytosis.

### Claim 98 (depends on 97)

The kit of claim 97, wherein said first container comprises a panel of antibodies selected from the group consisting of anti-CD11a, anti-CD11b, anti-CD14, anti-CD16, anti-CD49e, anti-CD62L, anti-CD64, IgG, NHK-L16, anti-CD32, anti-CD40, anti-CD86, 41H16, anti-ANCA and anti-proteinase-3.

### Claim 99 (depends on 97)

The kit of claim 97, wherein said first container comprises a panel of antibodies comprising anti-CD40 and anti-CD86.

### Claim 100 (depends on 97)

The kit of claim 97, wherein said first container comprises a panel of antibodies comprising anti-CD49e and anti-CD32.

### Claim 101 (depends on 97)

The kit of claim 97, further comprising reagents to detect fibronectin fragments.

### Claim 102 (depends on 101)

The kit of claim 101, wherein said fibronectin fragments are 110 kD or 120 kD.

### Claim 103 (depends on 97)

The kit of claim 97, further comprising a fluorochrome to measure reactive oxygen intermediates.

### Claim 104 (depends on 97)

The kit of claim 97, wherein phagocytosis is determined by measuring the levels of fluorochrome labeled microorganisms or other particles.

### Claim 105 (depends on 97)

The kit of claim 97, further comprising a fluorochrome to measure reactive oxygen intermediates.

### Claim 106 (depends on 105)

The kit of claim 105, wherein reactive oxygen intermediates are generated spontaneously or induced by the addition of bacteria.
